PAP
VTGN icon

Persistent Asset Partners’s VistaGen Therapeutics VTGN Stock Holding History

Persistent Asset Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-287
Closed -$3 – 484
2025
Q4 		$3 Buy
287
+56
+24% +$202 ﹤0.01% 359
2025
Q3 		$28.7K Buy
+231
New +$690 0.02% 198

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Persistent Asset Partners's VTGN Position: Q1 2026 in Review

Persistent Asset Partners held its VistaGen Therapeutics (VTGN) position steady in Q1 2026 at 26,612 shares worth $15.2K. The position accounts for 0.01% of the portfolio, ranked #281.

Persistent Asset Partners first reported a position in VTGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $352K in Q4 2024. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Persistent Asset Partners held 26,612 shares of VistaGen Therapeutics worth $15.2K as of Q1 2026.
  • Persistent Asset Partners left its VistaGen Therapeutics share count unchanged in Q1 2026.
  • VistaGen Therapeutics made up 0.01% of Persistent Asset Partners's portfolio in Q1 2026, its #281 holding.
  • Persistent Asset Partners first reported a position in VistaGen Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Persistent Asset Partners's VistaGen Therapeutics position peaked at $352K in Q4 2024.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.